Month: February 2017

American virologist Robert Gallo joined Medisun Medical Group

The famous American virologist – HIV virus discoverer Robert Gallo joined Medisun Medical Groupedisun

Bringing the best cancer and AIDS treatment technologies to China

Robert Gallo, a famous American virologist, joined Medisun Medical Groupedisun

In February 2017, Medisun Medical Group officially announced the appointment of Robert Charles Gallo, a famous American virologist, as a member of the board of directors of the group.

https://pbs.twimg.com/profile_images/461587078824738817/w8khfwWL.jpeg 

Dr. Robert Charles Gallo

Dr. Gallo is a famous American virologist whose best-known contribution is the discovery of the first human retrovirus (HTLV1, and HTLV2). In 1983, HTLV3 was discovered, which was later called the HIV, a virus that causes AIDS. He also studied the cytokine leukocyte 2, and in 1986 studied the pathogen human rash type 6 virus in children with acute rash. In 1982 and 1984, he received the Lasker Basic Medical Research Award (known as the “Nobel Prize in the United States”), the Charles Mott Award (Tumor Prevention Contribution Award) in 1984, and the Dickson International Award in 1985, 1988. Received the National Science and Technology Outstanding Contribution Award from Japan. Dr. Gallo is currently the Director of the Institute of Human Virology (IHV) at the University of Maryland and the founder and chief scientist of the Global Virus Network (GVN). He has served in the National Cancer of the United States. The National Cancer Institute has served as the director of the Laboratory of Cancer Cell Biology for 30 years. Dr. Gallo proposed the theory that the tumor system is caused by viruses and gradually improved its academic structure and clinical research.

Mr. Terry L. Lierman, founder of the US FDA, joined Medisun

At the same time , Mr.Terry L. Lierman entered the board of Medisun. Mr. Lierman is the founder of Summit Global Ventures and the CEO of Health Ventures LLC.Mr. Lierman has served on the US Senate Appropriations Committee and served as Director of the Sub-Committee on Labor Health and Human Services (HHS) Grants. Mr. Lierman is also the founder of Research America and NIH (National Institutes of Health) / FDA (US Food and Drug Administration) Board of Directors, and serves as the majority leader and member of the House of Representatives. He began his career in the health field of the NIH (National Institutes of Health) in 1971, where he assisted with budget and policy development, grants and contracts. For the past four decades, he has combined entrepreneurs and political talent in a variety of businesses.From leadership positions in the US Senate Appropriations Committee, founding companies and non-profit organizations, to promote health care advocacy, to lead and serve as chairman of the Maryland Democratic Party.

Mr.Terry L.Lierman

Chairman Medisun Wang Xiaofeng joined the Board of Directors of the Institute of Human Virology and the International Virus Alliance

At the same time that two world-class companies joined Medisun, Mr. Wang Xiaofeng, Chairman of Medisun Medical Group, was also invited to the Institute of Human Virology (IHV) and the Global Virus Network (GVN) at the University of Maryland as a member of the board of directors. Mr. Wang is the founder and chairman of the Board of Directors of Medisun Medical Group living in Canada and the United States for ten years. He moved to Hong Kong in 1996. Mr. Wang has more than 20 years of experience in the global capital market and medical industry, including industries including Medisunne, internet, education and media. Mr. Wang is currently Chairman of Hong Kong-listed National Investment Fund (01227.HK) and Chairman of Beijing Financial Group.

Mr. Danny Wong

Headquartered in Hong Kong, Medisun Medical Group is a professional medical investment group dedicated to the research and development and commercialization of global regenerative Medisunne products, as well as top hospitals and treatment centers.

Medisun invests extensively in the fields of regenerative Medisunne and stem cell patent technology, including stem cell therapy for heart failure, stem cell therapy for liver disease, kidney disease, nervous system disease, cancer, AIDS, and immune cell therapy for a variety of cancers. Medisun Medical has a long-term cooperation plan with the US-Australia Clinic, the Harvard University Stem Cell Institute, and the Johns Hopkins Medical School Life Science Center to jointly invest in regenerative Medisunne and stem cell therapy technology, with Medisun as a co-operative business. The Medisun holding entity and holds global intellectual property rights.

The Medisun Reproductive Medisunne Centre is located at the Proud Square in Kowloon Bay, Hong Kong. It has a 50,000 square foot stem cell GMP production base, a cancer treatment centre and an anti-aging centre. It brings together European, Japanese, American and individual Chinese experts to develop a rigorous and professional R&D process. Provides immune cell therapy and a variety of stem cell health treatments. As the Asian service organization of Mayo Clinic, the center provides Mayo remote consultation and secondary treatment to enable Chinese patients to enjoy authoritative medical services without leaving the country. 3,300 biomedical tests provide the most predictable health protection for customers’ health, adding more than 300 new testing items each year.

MEDISUN REGENERATIVE MEDICAL CENTER | CANCER TREATMENT CENTER | ANTI-AGING CENTER

Medisun Medical Laboratory (Hong Kong)

Medisun Medical Laboratory (Hong Kong)

Medisun announced that he will join the Biden Cancer Lunar Plan

At the end of 2016, Medisun announced that he would join the “Cancer Moon Plan” initiated by former US Vice President Biden. The “Cancer Moon Plan” was proposed by former US President Obama in early 2016 and was initiated by former Vice President Biden. The goal is to shorten the work schedule for cancer-related prevention, diagnosis, treatment and care that was expected to be completed in 5 years. Aiming to achieve 20,000 cancer treatments worldwide by 60 programs by 2020.
Dr. Gallo and Mr. Lierman will lead Medisun’s clinical research implementation, medical technology and project selection, medical resource introduction, etc., and bring the best technology in the world to China, highlighting the inevitable trend of China’s participation in the world’s most advanced technology research and development. . At the same time, Medisun’s clinical research bases in Hong Kong, Beijing, Shanghai, Guangzhou and Tokyo will participate in the world’s most advanced clinical research.
Dr. Gallo and Mr. Lierman joined Medisun and Chairman Wang Xiaofeng to enter the IHV and GVN Board of Directors, indicating that Medisun will work with IHV and GVN to make valuable preparations for the cancer landing program and to fully participate in the global research and development of cancer treatment.

The Human Virology Institute (IHV) is the world’s first research center that combines basic science, epidemiology and clinical research disciplines to accelerate the diagnosis and treatment of chronic viruses and immune diseases (mostly HIV, AIDS the reason). IHV’s laboratory is a US key laboratory that receives more than $200 million in annual US research funding.
Founded in 1996 as a partner of the University of Maryland, IHV is a research institute at the University of Maryland School of Medisun, bringing together a globally recognized and world-renowned expert in human virology. The IHV was co-founded by Robert Gallo (Director of IHV) and William Blattner.MD. The IHV also includes the Animal Model Department, the Basic Science Department and the Vaccine Research Department.
The institute has a variety of laboratory and patient care facilities located in Baltimore, Maryland. IHV has created an environment of close collaboration between multidisciplinary research, education and clinical research and development, accelerating scientific understanding of the incidence of HIV/AIDS, and developing interventions to curing cancers of HIV and viruses possible.
IHV’s research focuses on how to use the body’s natural chemistry to its own therapeutic potential, and to discover biotherapeutics that are less toxic to the body and more economical for the public. IHV is also committed to developing effective therapeutic and preventive vaccines that are dedicated to ending the AIDS epidemic.
IHV has more than 300 employees, including 70 professors, whose research focuses on chronic human viral infections and diseases. Currently, more than 75% of the Institute’s clinical and research work addresses HIV infection, but also includes hepatitis C virus, human T-cell leukemia virus 1 and 2, human papillomavirus, herpes virus and cancer research. The patient base of IHV has grown from just 200 patients to about 6,000 in Baltimore, and nearly 1 million in 6 African and 1 Caribbean countries.

The Global Network of Viruses (GVN) is a global organization for the research of viral diseases. It is a consortium of authoritative virologists from more than 20 countries around the world. It is dedicated to the research, development of drugs and vaccines to prevent diseases and death. GVN is the only single organization in the world that has special research in all areas of the virus. GVN brings together the world’s best medical virology experts to focus on difficult scientific issues around the world. The strength of GVN lies in its global reach, the depth of science, and its vision to address the viral challenges facing humanity.

GVN achieves its goals through three strategic action platforms:

Support research

Public education

Advocate a statement supporting the global virus network

Established in Washington, DC, the organization supports the goals and ideals of a global virus network, actively trains younger generations of medical virologists, and provides advice to governments or NGOs on viral diseases to fill the current international health development important needs.

Source: http://www.medisun.hk/

By Science

Mig Welder Ireland

Looking for plasma cutter for a project in Ireland? You can check this complete welding solutions online store at Migwelders.ie.

Oxford Welder provider Ireland : MIG Welders are extremely popular because they tend to cost less than TIG or Stick welders with comparable power and features, are extremely easy to learn, and can tackle a wide variety of projects. Since the filler metal is fed through the MIG welding torch, welders can use both hands to hold the torch steady rather than using one hand to add filler metal, as in TIG welding. The wire feeder also makes MIG welding up to four times faster.

The MIG welding process uses an inert gas to shield the weld and to keep it free from impurities. This makes MIG welding very neat and easy to clean up since there isn’t anything to chip away, which is typical for Stick welding.

Some tips on choosing the best welding equipment and also some industry news:

Weight of machine Do you require a machine that needs to be moved around and transported to jobs, or will it remain within a workshop?

Take into account the duty cycle of the machine!! You may need 160amps and a machine may state that it does this, but it could only be at 15% duty cycle, which means it could only weld at 160amps for 1.5mins out of every 10mins? Unless you are only do very short welds its best to work on a 35% duty cycle when choosing your machine.

Where the machine is manufactured and are replacement parts available in your country? Time and time again we have customers who cannot get spares for their machine when it breaks down. MigWelder.Ie has all the spare parts for all the machines on the shop.

Purchasing a welder is an important long term decision that can add extra income to your bottom line, save on repair costs, and make it possible to complete a wide array of hobbies. The options can be overwhelming, and that is why we’ve put together this welder buying guide. You’ll find important details to consider, a comparison of welder types, and information about the top selling brands from Baker’s Gas and Welding.

One of the most important questions to consider when selecting a welder isn’t what projects it will be used for in the next week, month, or even year. Those interested in buying a welder need to ask if they see themselves using it more frequently in the future for many different kinds of projects.

TWS Direct Ltd. Unit 1 M54 Space Centre.
Halesfield 8. Telford. Shropshire. TF7 4QN
Phone :
+44 (0) 1952 582 260
Website: https://www.migwelders.ie/
Email :sales@weldingsuppliesdirect.co.uk; MIGWELDERS.IE are a welding equipment and welding consumables supplier based in Shropshire, UK. We strive to provide the best MIG welders, TIG welders and welding consumables in Ireland. We are the home of Oxford welders in Ireland, with plenty of machines carried in stock for fast delivery!

By Shopping , , ,

The famous american virologist Robert Gallo joined Medisun Medical Group

The famous American virologist – HIV virus discoverer Robert Gallo joined Medisun Medical Groupedisun

Bringing the best cancer and AIDS treatment technologies to China

Robert Gallo, a famous American virologist, joined Medisun Medical Groupedisun

In February 2017, Medisun Medical Group officially announced the appointment of Robert Charles Gallo, a famous American virologist, as a member of the board of directors of the group.

https://pbs.twimg.com/profile_images/461587078824738817/w8khfwWL.jpeg 

Dr. Robert Charles Gallo

Dr. Gallo is a famous American virologist whose best-known contribution is the discovery of the first human retrovirus (HTLV1, and HTLV2). In 1983, HTLV3 was discovered, which was later called the HIV, a virus that causes AIDS. He also studied the cytokine leukocyte 2, and in 1986 studied the pathogen human rash type 6 virus in children with acute rash. In 1982 and 1984, he received the Lasker Basic Medical Research Award (known as the “Nobel Prize in the United States”), the Charles Mott Award (Tumor Prevention Contribution Award) in 1984, and the Dickson International Award in 1985, 1988. Received the National Science and Technology Outstanding Contribution Award from Japan. Dr. Gallo is currently the Director of the Institute of Human Virology (IHV) at the University of Maryland and the founder and chief scientist of the Global Virus Network (GVN). He has served in the National Cancer of the United States. The National Cancer Institute has served as the director of the Laboratory of Cancer Cell Biology for 30 years. Dr. Gallo proposed the theory that the tumor system is caused by viruses and gradually improved its academic structure and clinical research.

Mr. Terry L. Lierman, founder of the US FDA, joined Medisun

At the same time , Mr.Terry L. Lierman entered the board of Medisun. Mr. Lierman is the founder of Summit Global Ventures and the CEO of Health Ventures LLC.Mr. Lierman has served on the US Senate Appropriations Committee and served as Director of the Sub-Committee on Labor Health and Human Services (HHS) Grants. Mr. Lierman is also the founder of Research America and NIH (National Institutes of Health) / FDA (US Food and Drug Administration) Board of Directors, and serves as the majority leader and member of the House of Representatives. He began his career in the health field of the NIH (National Institutes of Health) in 1971, where he assisted with budget and policy development, grants and contracts. For the past four decades, he has combined entrepreneurs and political talent in a variety of businesses.From leadership positions in the US Senate Appropriations Committee, founding companies and non-profit organizations, to promote health care advocacy, to lead and serve as chairman of the Maryland Democratic Party.

Mr.Terry L.Lierman

Chairman Medisun Wang Xiaofeng joined the Board of Directors of the Institute of Human Virology and the International Virus Alliance

At the same time that two world-class companies joined Medisun, Mr. Wang Xiaofeng, Chairman of Medisun Medical Group, was also invited to the Institute of Human Virology (IHV) and the Global Virus Network (GVN) at the University of Maryland as a member of the board of directors. Mr. Wang is the founder and chairman of the Board of Directors of Medisun Medical Group living in Canada and the United States for ten years. He moved to Hong Kong in 1996. Mr. Wang has more than 20 years of experience in the global capital market and medical industry, including industries including Medisunne, internet, education and media. Mr. Wang is currently Chairman of Hong Kong-listed National Investment Fund (01227.HK) and Chairman of Beijing Financial Group.

Mr. Danny Wong

Headquartered in Hong Kong, Medisun Medical Group is a professional medical investment group dedicated to the research and development and commercialization of global regenerative Medisunne products, as well as top hospitals and treatment centers.

Medisun invests extensively in the fields of regenerative Medisunne and stem cell patent technology, including stem cell therapy for heart failure, stem cell therapy for liver disease, kidney disease, nervous system disease, cancer, AIDS, and immune cell therapy for a variety of cancers. Medisun Medical has a long-term cooperation plan with the US-Australia Clinic, the Harvard University Stem Cell Institute, and the Johns Hopkins Medical School Life Science Center to jointly invest in regenerative Medisunne and stem cell therapy technology, with Medisun as a co-operative business. The Medisun holding entity and holds global intellectual property rights.

The Medisun Reproductive Medisunne Centre is located at the Proud Square in Kowloon Bay, Hong Kong. It has a 50,000 square foot stem cell GMP production base, a cancer treatment centre and an anti-aging centre. It brings together European, Japanese, American and individual Chinese experts to develop a rigorous and professional R&D process. Provides immune cell therapy and a variety of stem cell health treatments. As the Asian service organization of Mayo Clinic, the center provides Mayo remote consultation and secondary treatment to enable Chinese patients to enjoy authoritative medical services without leaving the country. 3,300 biomedical tests provide the most predictable health protection for customers’ health, adding more than 300 new testing items each year.

MEDISUN REGENERATIVE MEDICAL CENTER | CANCER TREATMENT CENTER | ANTI-AGING CENTER

Medisun Medical Laboratory (Hong Kong)

Medisun Medical Laboratory (Hong Kong)

Medisun announced that he will join the Biden Cancer Lunar Plan

At the end of 2016, Medisun announced that he would join the “Cancer Moon Plan” initiated by former US Vice President Biden. The “Cancer Moon Plan” was proposed by former US President Obama in early 2016 and was initiated by former Vice President Biden. The goal is to shorten the work schedule for cancer-related prevention, diagnosis, treatment and care that was expected to be completed in 5 years. Aiming to achieve 20,000 cancer treatments worldwide by 60 programs by 2020.
Dr. Gallo and Mr. Lierman will lead Medisun’s clinical research implementation, medical technology and project selection, medical resource introduction, etc., and bring the best technology in the world to China, highlighting the inevitable trend of China’s participation in the world’s most advanced technology research and development. . At the same time, Medisun’s clinical research bases in Hong Kong, Beijing, Shanghai, Guangzhou and Tokyo will participate in the world’s most advanced clinical research.
Dr. Gallo and Mr. Lierman joined Medisun and Chairman Wang Xiaofeng to enter the IHV and GVN Board of Directors, indicating that Medisun will work with IHV and GVN to make valuable preparations for the cancer landing program and to fully participate in the global research and development of cancer treatment.

The Human Virology Institute (IHV) is the world’s first research center that combines basic science, epidemiology and clinical research disciplines to accelerate the diagnosis and treatment of chronic viruses and immune diseases (mostly HIV, AIDS the reason). IHV’s laboratory is a US key laboratory that receives more than $200 million in annual US research funding.
Founded in 1996 as a partner of the University of Maryland, IHV is a research institute at the University of Maryland School of Medisun, bringing together a globally recognized and world-renowned expert in human virology. The IHV was co-founded by Robert Gallo (Director of IHV) and William Blattner.MD. The IHV also includes the Animal Model Department, the Basic Science Department and the Vaccine Research Department.
The institute has a variety of laboratory and patient care facilities located in Baltimore, Maryland. IHV has created an environment of close collaboration between multidisciplinary research, education and clinical research and development, accelerating scientific understanding of the incidence of HIV/AIDS, and developing interventions to curing cancers of HIV and viruses possible.
IHV’s research focuses on how to use the body’s natural chemistry to its own therapeutic potential, and to discover biotherapeutics that are less toxic to the body and more economical for the public. IHV is also committed to developing effective therapeutic and preventive vaccines that are dedicated to ending the AIDS epidemic.
IHV has more than 300 employees, including 70 professors, whose research focuses on chronic human viral infections and diseases. Currently, more than 75% of the Institute’s clinical and research work addresses HIV infection, but also includes hepatitis C virus, human T-cell leukemia virus 1 and 2, human papillomavirus, herpes virus and cancer research. The patient base of IHV has grown from just 200 patients to about 6,000 in Baltimore, and nearly 1 million in 6 African and 1 Caribbean countries.

The Global Network of Viruses (GVN) is a global organization for the research of viral diseases. It is a consortium of authoritative virologists from more than 20 countries around the world. It is dedicated to the research, development of drugs and vaccines to prevent diseases and death. GVN is the only single organization in the world that has special research in all areas of the virus. GVN brings together the world’s best medical virology experts to focus on difficult scientific issues around the world. The strength of GVN lies in its global reach, the depth of science, and its vision to address the viral challenges facing humanity.

GVN achieves its goals through three strategic action platforms:

Support research

Public education

Advocate a statement supporting the global virus network

Established in Washington, DC, the organization supports the goals and ideals of a global virus network, actively trains younger generations of medical virologists, and provides advice to governments or NGOs on viral diseases to fill the current international health development important needs.

Source: http://www.medisun.hk/

By Health

Blockchain developers UAE

The blockchain is an undeniably ingenious invention the brainchild of a person or group of people known by the pseudonym, Satoshi Nakamoto. But since then, it has evolved into something greater, and the main question every single person is asking is: What is Blockchain?

By allowing digital information to be distributed but not copied, blockchain technology created the backbone of a new type of internet. Originally devised for the digital currency, Bitcoin, (Buy Bitcoin) the tech community is now finding other potential uses for the technology.

If only time travel were possible then majority of people would wish to back in 2010 to buy bitcoins. A mere 10,000 rupees invested in bitcoins back then would have fetched you over mind boggling 330 crores by now! The world was stunned with such a phenomenal growth of bitcoins as a cryptocurrency. Keep reading this post as we will explain about bitcoin shortly. But how could such a currency grow stupendously on a global scale? The answer is Blockchain. Simple as it may sound there are huge mechanisms in place in making the technology work. The time spent by IBM global financing was reduced by 75% in solving financial disputes using Blockchain technology. Did you know that in international trade finance and remittances ICICI bank using Blockchain technology successfully executed transactions? Did you know SBI is using it in its KYC norms and smart projects? Did you know that Azure is already providing Blockchain as a service(BaaS)? And these are just three instances of the applications of Blockchain and the most obvious use case is bitcoin.

A blockchain is a decentralized digital ledger that saves transactions on thousands of computers around the globe. These are registered in a way that inhibits their subsequent modification. Blockchain technology increases the security and speeds up the exchange of information in a way that is cost-effective and more transparent. It also dispenses with third parties whose main role was to provide a trust and certification element in transactions (such as notaries and banks).

Today we are taking a look at an UAE blockchain developer software company, Leeway Hertz – blockchain developers

They provide various services including : Permissioned and Permissionless Blockchain Development. We have completed permissioned and permissionless blockchain development for startups and enterprises.

Development Portfolio example:

Freight Tracking

Freight tracking solution enables shippers, logistics companies, brokers and carriers to track shipments with increased accuracy in real time. The platform handles data exchange and transactions securely over the blockchain platform, ensuring shipments without delays and frauds. The platform can handle millions of events without friction and track shipments end-to-end.

We convert ideas into practical applications that are scalable and reliable. We recommend following a process to test quickly and get product maturity at early stages. With the experience of building 100+ digital platforms for clouds, apps, and blockchain companies, we have tailored our process to match the ongoing blockchain industry changes.

Blockchain Ideation

Brainstorm idea and business requirements
Identify any existing system migration to Distributed Ledger
Prioritize use cases in Fail fast, MVP & v2.0
Define off chain & on chain business entities
Define technical component
Roadmap of the product

Supporting the following platforms:

1. Ethereum – A decentralized public platform that runs dApps
2. Hyperledger – A provisioned private network meant to share data and process for enterprises
3. R3 – A solution for managing financial agreements
4. Stellar – Stellar is an open platform for building financial products that connect people everywhere.
5. EOS – EOS is a decentralized blockchain, which can process fast and free transactions.
6. Hashgraph – Fair, Fast and most secured acrylic graph DLT.
7. Corda – Corda is an open source blockchain platform for businesses.
8. Credits – Credits blockchain platform manages for creates financial services based on blockchain/ledger
9. NEO – NEO is a blockchain platform designed to build a scalable network of decentralized applications.

By Software , ,

GreenSpace Brands Announces Acquisition of US Based Galaxy Nutritional Foods, Owners of the Go Veggie Brand

GreenSpace Brands Inc. (“GreenSpace”) (TSXV: JTR) is pleased to announce today that it has signed a share purchase agreement dated December 20, 2017 to acquire (the “Acquisition”) all of the outstanding shares of Galaxy Nutritional Foods Inc. (“Go Veggie”), which owns the Go Veggie? brand. Go Veggie is one of the leading cheese alternative brands in the United States with distribution in over 12,000 locations through most major US grocery retailers and natural food chains, along with a growing food service business. The plant based dairy alternative market is one of the fastest growing subsets of the natural food market, but has very few established players. Go Veggie has established itself as one of the preeminent brands in the space with some of the best tasting and award winning products.

Greenspace will be holding a conference call to discuss the details of the transaction on December 21st, 2017 at 9:00 EST. The call will be hosted by Matthew von Teichman, President and Chief Executive Officer. Following management’s presentation, there will be a question and answer session for analysts and investors. To participate in the teleconference, dial (647) 427-7450 or 1 (888) 231-8191 (Toll-free). Callers are advised to call five minutes in advance of the call.

A taped rebroadcast will be available beginning at 11:20 am (EST) December 21st, 2017 until 11:59 pm (EST) on December 28th, 2017. To access the rebroadcast, please dial (416) 849-0833 or 1 (855) 859- 2056 and use the passcode 1289656 followed by the number sign.

Overview of the Acquisition

GreenSpace has agreed to purchase Go Veggie for a total consideration of $17.8 million USD, comprised of $4.5 million USD in cash, $7.62 million USD (approximately $9.81million CAD) in GreenSpace common shares (the “Share Consideration”), and a two year vendor take back loan of $5.72 million USD, carrying an 8.5% coupon. Greenspace will issue 7.16 million Common shares at $1.37 per share as part of the transaction, a 14.2% premium to the closing market price on December 19th, 2017.

GreenSpace will be purchasing Go Veggie from Mill Road Capital, a Greenwich, Connecticut based private investment firm focused on investing in and partnering with publicly traded micro-cap companies. Mill Road will become the largest shareholder of GreenSpace as a result of this transaction. Mill Road Capital has a long history of successfully investing in emerging consumer brands throughout Canada and the United States, and this expertise will help support the GreenSpace team as they navigate the US natural food market and US capital markets.

The Share Consideration will be subject to lock-up and escrow pursuant to which approximately 45% of the Share Consideration shall be locked up for 12 months from the closing date, 5% of the Share Consideration shall be in escrow for 13 months from the closing date and the remaining 50% shall be locked-up for 18 months from the closing date, subject to certain exemptions.

Select highlights of the Acquisition include the following:

Go Veggie adds a profitable pre-existing US platform that will enable GreenSpace to launch its most innovative and unique brands into the US;

The acquisition is expected to add significant gross margin dollars to GreenSpace and improve the overall gross margin profile, as well as add incremental adjusted EBITDA in the short term, with more significant growth in adjusted EBITDA over the long term. Go Veggie recorded revenues of $16.3 million USD for their fiscal year ended March, 31, 2017, with strong gross profit margins of approximately 40%.1
Go Veggie has one of the leading brands in what GreenSpace believes to be one of the fastest growing segments of the natural food industry, plant based dairy alternatives. Galaxy has broad based distribution across the United States and an existing high functioning team; and

GreenSpace believes that by supporting updates and amplifying the brand image of Go Veggie, it will be able to further develop its leadership position in the plant based dairy alternatives vertical in North America;

“We couldn’t be more excited to add Go Veggie to the GSB family of brands. With the acquisition of Go Veggie, we enter our most sought after vertical, plant based dairy alternatives. The addition of Go Veggie adds a profitable pre-existing US platform that will enable us to launch our most innovative and unique brands into the US under the expert leadership of one of the most respected people in the US natural food industry, Rick Antonelli, CEO of Go Veggie” comments Matthew von Teichman, CEO of Greenspace, “This is truly a transformative acquisition for us. We will continue to develop their Canadian sales strategy through the leveraging of our current platform and strategically initiate our US development by leveraging their platform. It’s a win-win and the ideal way for us to get going in the US market”

Rick Antonelli, CEO of Galaxy comments, “We’ve been watching GreenSpace for years and have admired the stable of brands they’ve been able to put together in such a short time. We feel that Go Veggie is a perfect addition to that roster of strong brands and with the potential synergies of our team selling their products, and their team selling our products, there’s a significant long term upside for both. I can’t wait to start presenting GreenSpace’s unique and innovative products to the US market and Go Veggie’s existing retail partners.”

The Acquisition is scheduled to close in January 2018, subject to satisfaction of customary closing conditions and approval of the TSX Venture Exchange. Financo, Inc. has acted as the exclusive advisor to Galaxy and Mill Road.

About GreenSpace

GreenSpace is a Canadian-based brand ideation team that develops, markets and sells premium natural food products to consumers across Canada. Greenspace owns and operates the following brands: Love Child Organics., one of the fastest growing brands in Canada and a producer of 100% organic food for infants and toddlers made with the pure, natural and most nutritionally-rich ingredients; Central Roast, a clean snacking brand that has been one of the leading natural food brands in Canada; Rolling Meadow Dairy, Canada’s leading grass fed dairy product line, delivering premium fluid and cultured products across Canada; Life Choices which features premium convenience meat products made with grass fed and pasture raised meats without the use of added hormones and antibiotics; Kiju, the Canadian market leader in the shelf stable organic juice segment; Cedar , the Canadian leader in cold pressed and gut health fresh juices. All brands are wholly owned and retail in a variety of natural and mass retail grocery locations across Canada.

GreenSpace’s filings are also available at www.SEDAR.com

About GO VEGGIE?

Over 40 years ago Galaxy Nutritional Foods Inc. created the cheese alternative category for health-conscious consumers and is proud to remain America’s leading provider of great tasting cheese-free products. Today, under Galaxy’s new brand GO VEGGIE, the company continues to innovate and offer consumers more healthy cheese-free choices. Across its product portfolio – Vegan, Lactose Free, and Lactose & Soy Free – GO VEGGIE offers 55 products across the United States in a wide variety of formats.

For product information, recipes, and more, visit www.goveggiefoods.com. Follow GO VEGGIE on Facebook, Twitter, Instagram, and Pinterest.

About Mill Road Capital

Mill Road Capital is a private investment firm focused on investing in and partnering with publicly traded micro-cap companies in the U.S. and Canada. The firm has flexible, long-term capital with the ability to purchase shares in the open market, buy large block positions from existing shareholders, provide capital for growth or acquisition opportunities, or execute going-private transactions. The firm has raised approximately $670 million of aggregate equity capital commitments and has offices in Greenwich, CT and the San Francisco Bay Area. Mill Road’s investments in Canada include Ten Peaks Coffee Company, a British Colombia based premium green coffee decaffeinator, PRT Growing Services Ltd., the British Columbia based leader in container grown tree seedlings for replanting forests, and Cossette, the largest full service advertising agency in Canada.

More information can be found at http://www.millroadcapital.com.

Forward Looking Information

Certain statements in this press release may constitute forward-looking statements within the meaning of applicable securities laws. Forward-looking statements include, but are not limited to, statements concerning (i) the Acquisition; (ii) the completion of the Acquisition; (iii) anticipated approvals; (iv) the time to the closings; and (v) results of the completion of the Acquisition. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “outlook”, “objective”, “may”, “will”, “expect”, “intend”, “estimate”, “anticipate”, “believe”, “should”, “plans” or “continue”, or similar expressions suggesting future outcomes or events. Such forward-looking statements reflect management’s current beliefs and are based on information currently available to management. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those contemplated by such statements. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements including, without limitation, the risks that: (1) the information provided to GreenSpace by Galaxy turns out to be misleading, untrue or incomplete; (2) the Acquisition may not be completed for any reason whatsoever, including that regulators may not approve the Acquisition; (3) the closings may not occur as scheduled or at all; and (4) GreenSpace may not achieve the results currently anticipated. Although GreenSpace believes that the expectations reflected in its forward-looking information are reasonable, undue reliance should not be placed on forward-looking information because GreenSpace can give no assurance that such expectations will prove to be correct. In addition to other factors and assumptions which may be identified in this press release, assumptions have been made regarding and are implicit in, among other things, the timely receipt of required regulatory approvals. Details of the risk factors relating to GreenSpace and its business are discussed under the heading “Risk Factors” in the preliminary short form prospectus filed on the date hereof and “Risks and Uncertainties Related to the Business” in GreenSpace’ annual information form dated July 18, 2017, a copy of which is available on GreenSpace’ SEDAR profile at www.sedar.com. Readers are cautioned that the foregoing list is not exhaustive of all factors and assumptions which have been used. Forward-looking information is based on current expectations, estimates and projections that involve a number of risks and uncertainties which could cause actual results to differ materially from those anticipated by GreenSpace and described in the forward looking information. The forward-looking information contained in this press release is made as of the date hereof and GreenSpace undertakes no obligation to update publicly or revise any forward-looking information, whether as a result of new information, future events or otherwise, unless required by applicable securities laws. The forward looking information contained in this press release is expressly qualified by this cautionary statement.

Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This press release does not constitute or form a part of any offer or solicitation to buy or sell any securities in the United States or any other jurisdiction.

By Food , , ,